OraSure Technologies, Inc. (NASDAQ:OSUR - Get Free Report) CFO Kenneth Mcgrath bought 22,021 shares of the stock in a transaction on Friday, March 13th. The stock was purchased at an average price of $3.00 per share, for a total transaction of $66,063.00. Following the completion of the purchase, the chief financial officer owned 557,262 shares of the company's stock, valued at approximately $1,671,786. This trade represents a 4.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
OraSure Technologies Price Performance
Shares of NASDAQ OSUR opened at $3.13 on Tuesday. The stock has a market capitalization of $216.38 million, a PE ratio of -3.37 and a beta of 0.88. OraSure Technologies, Inc. has a one year low of $2.08 and a one year high of $4.22. The business's fifty day moving average price is $2.83 and its 200-day moving average price is $2.79.
OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). OraSure Technologies had a negative return on equity of 16.45% and a negative net margin of 59.76%.The firm had revenue of $26.76 million during the quarter, compared to analysts' expectations of $26.44 million. As a group, equities analysts expect that OraSure Technologies, Inc. will post -0.08 EPS for the current fiscal year.
Institutional Trading of OraSure Technologies
A number of institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd bought a new position in OraSure Technologies in the 4th quarter worth about $28,000. Prudential Financial Inc. bought a new stake in shares of OraSure Technologies during the second quarter valued at about $31,000. Nierenberg Investment Management Company Inc. bought a new stake in shares of OraSure Technologies during the second quarter valued at about $35,000. L2 Asset Management LLC purchased a new stake in shares of OraSure Technologies in the second quarter worth about $39,000. Finally, Coldstream Capital Management Inc. lifted its holdings in shares of OraSure Technologies by 128.2% in the second quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 7,477 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company's stock.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a "sell (d)" rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, OraSure Technologies currently has an average rating of "Reduce" and an average price target of $3.00.
Read Our Latest Stock Report on OraSure Technologies
About OraSure Technologies
(
Get Free Report)
OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.
The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
